PTC Therapeutics (NASDAQ:PTCT) Raised to “Neutral” at Bank of America
Bank of America upgraded shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from an underperform rating to a neutral rating in a research note published on Tuesday morning, MarketBeat Ratings reports. They currently have $55.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $41.00. Several other brokerages have also […]
Bank of America upgraded shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from an underperform rating to a neutral rating in a research note published on Tuesday morning, MarketBeat Ratings reports. They currently have $55.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $41.00. Several other brokerages have also […]
